ArticleActa pharmaceutica Sinica. B2021

Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression

Xiaoxia Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.